San Francisco-based Principia and partner AbbVie have elected to part ways on a collaboration they signed about two years ago, which handed the newly public biotech $15 million upfront.
The drug developer, run by a troop of executives drawn from Roche, joined forces with AbbVie in June 2017 to develop oral immunoproteasome inhibitors for inflammatory and autoimmune disorders. Immunoproteasome is a family of proteasome — the cell’s protein recyclers — found abundantly in immune cells, which play a role in immune responses, affecting antigen presentation, T cell function and cytokine production.
The collaboration could have given Principia — which went public last year in an upsized $108 million IPO — up to $667.5 million in milestone payments, in addition to tiered royalty on sales. At the moment, the program is in advanced lead optimization (the stage that precedes preclinical testing).
Principia $PRNB, which also counts Sanofi as partner, has a BTK inhibitor as its lead drug — PRN1008 — designed for autoimmune diseases, and is currently in a late-stage study for rare cases of a chronic skin condition called pemphigus.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,200+ biopharma pros who read Endpoints News by email every day.Free Subscription